Shop By
Catalog No.
Product Name
Application
Product Information
Citations
-
HSD17B13 Inhibitor
HSD17B13-IN-102 is a potent inhibitor of the enzyme hydroxysteroid dehydrogenase 17 beta 13 (HSD17B13), demonstrating an IC50 value of less than 0.1 μM with estradiol. This compound is instrumental in research focused on steroid metabolism and associated diseases, particularly in the context of liver function and metabolic disorders. Its selective inhibition provides a valuable tool for investigating the biological roles of HSD17B13 in various physiological and pathological conditions. -
17β-HSD Inhibitor
HSD17B13-IN-16 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), exhibiting an IC50 of less than 0.1 μM for estradiol and less than 1 μM for leukotriene B3. This compound has significant relevance in the study of nonalcoholic fatty liver diseases (NAFLDs), including nonalcoholic steatohepatitis (NASH). HSD17B13-IN-16 serves as a valuable tool for researchers investigating metabolic disorders and potential therapeutic interventions in liver diseases. -
17β-HSD Inhibitor
HSD17B13-IN-35 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), exhibiting an IC50 of less than 0.1 μM when estradiol is used as a substrate. This compound is significant in the context of nonalcoholic fatty liver diseases (NAFLDs), including nonalcoholic steatohepatitis (NASH), by targeting metabolic pathways involved in lipid metabolism. Its effective inhibition of HSD17B13 makes it a valuable reagent for research into therapeutic strategies for liver-related disorders. -
HSD17B13 Inhibitor
HSD17B13-IN-63 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), demonstrating an IC50 value of ≤ 0.1 μM for estradiol. This compound is valuable for research applications related to liver diseases, metabolic disorders, and cardiovascular conditions, including non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and drug-induced liver injury (DILI). Its efficacy in modulating HSD17B13 activity provides insights into the underlying mechanisms of these diseases. -
HSD17B13 Inhibitor
HSD17B13-IN-57 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), exhibiting an IC50 value of ≤ 0.1 μM for estradiol. This compound is relevant for investigations into liver diseases, metabolic disorders, and cardiovascular conditions, including non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and drug-induced liver injury (DILI). HSD17B13-IN-57 serves as a valuable tool for studying the biochemical pathways involved in these diseases. -
17β-HSD Inhibitor
HSD17B13-IN-28 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), exhibiting an IC50 of less than 0.1 μM for estradiol as substrate. This compound is significant in the study of nonalcoholic fatty liver diseases (NAFLDs), including nonalcoholic steatohepatitis (NASH). Its ability to modulate HSD17B13 activity makes it a valuable tool for exploring the metabolic mechanisms underpinning liver disorders and evaluating potential therapeutic strategies. -
HSD17B13 Inhibitor
HSD17B13-IN-100 is a potent inhibitor of HSD17B13, exhibiting an IC50 value of less than 0.1 μM in the presence of estradiol. This compound is essential for researchers investigating the role of HSD17B13 in steroid metabolism and related pathways. Its selective inhibition can facilitate studies on various conditions associated with altered steroidogenesis, including liver diseases and metabolic disorders. -
HSD17B13 Inhibitor
HSD17B13-IN-80 is a selective inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), exhibiting an IC50 value of ≤ 0.1 μM for estradiol. This compound plays a crucial role in research focusing on liver diseases, metabolic disorders, and cardiovascular conditions, including non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and drug-induced liver injury (DILI). Its potent inhibitory activity makes it a valuable tool for investigating the pathophysiological mechanisms underlying these diseases. -
HSD17B13 Inhibitor
HSD17B13-IN-44 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of less than 0.1 μM for estradiol. This compound is valuable for investigating its role in liver diseases and metabolic disorders, providing insights into the biochemical pathways associated with these conditions. Researchers can utilize HSD17B13-IN-44 to explore therapeutic targets and validate the significance of HSD17B13 in various biological processes. -
HSD17B13 Inhibitor
HSD17B13-IN-45 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), exhibiting an IC50 value of less than 0.1 μM for estradiol. This compound is instrumental in exploring pathways associated with liver diseases and metabolic disorders. Researchers can utilize HSD17B13-IN-45 to investigate the role of HSD17B13 in various biological contexts and its potential as a therapeutic target. -
HSD17B13 Inhibitor
HSD17B13-IN-81 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), exhibiting an IC50 value of ≤ 0.1 μM for estradiol. This compound is utilized in research focused on liver diseases, metabolic disorders, and cardiovascular diseases, including non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). Additionally, it serves as a valuable tool in studies related to drug-induced liver injury (DILI). -
17β-HSD Inhibitor
HSD17B13-IN-40 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 of less than 0.1 μM against estradiol substrates. This compound is significant for research related to nonalcoholic fatty liver diseases (NAFLD), particularly nonalcoholic steatohepatitis (NASH), as it may provide insights into the modulation of lipid metabolism and inflammatory pathways. The compound's inhibitory action on HSD17B13 highlights its potential utility in exploring therapeutic strategies for metabolic disorders. -
HSD17B13 Inhibitor
HSD17B13-IN-33 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of less than 0.1 μM for estradiol. This compound plays a crucial role in research focused on liver diseases, metabolic disorders, and cardiovascular conditions, including non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and drug-induced liver injury (DILI). Its selective activity makes it a valuable tool for investigating the therapeutic potential in these diseases. -
17β-HSD Inhibitor
HSD17B13-IN-30 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), demonstrating an IC50 of less than 0.1 μM for estradiol substrates. This compound is significant in the study of nonalcoholic fatty liver diseases (NAFLDs), including nonalcoholic steatohepatitis (NASH), due to its role in modulating steroid metabolism and fatty liver progression. HSD17B13-IN-30 facilitates research into therapeutic approaches for liver-related metabolic disorders. -
17β-HSD1 Inhibitor
17β-HSD1-IN-2 is a non-estrogenic, steroidal covalent irreversible inhibitor of 17β-Hydroxysteroid dehydrogenase type 1 (17β-HSD1), exhibiting a Ki of 368 nM. This compound demonstrates potential for studying estrogen-dependent disorders, facilitating research into therapeutic strategies for conditions influenced by estrogen metabolism. Its selective inhibition of 17β-HSD1 offers valuable insights into the enzyme's role in various biological processes and disease states. -
HSD17B13 Inhibitor
HSD17B13-IN-14 is a selective inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), exhibiting an IC50 of ≤ 1 μM for leukotriene B3 and ≤ 0.1 μM for estradiol. This compound is valuable for research into hepatic conditions, metabolic diseases, and cardiovascular disorders, including non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and drug-induced liver injury (DILI). Its potent inhibition of HSD17B13 makes it an important tool for studying the underlying mechanisms of these diseases. -
HSD17B13 Inhibitor
HSD17B13-IN-53 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), demonstrating an IC50 value of ≤ 0.1 μM for estradiol. This compound is valuable for research into liver-related pathologies, metabolic disorders, and cardiovascular diseases, including non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), as well as studies on drug-induced liver injury (DILI). -
HSD17B13 Inhibitor
HSD17B13-IN-47 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), exhibiting an IC50 value of less than 0.1 μM for estradiol. This compound is valuable for studying the role of HSD17B13 in liver diseases and metabolic disorders, facilitating research into therapeutic interventions targeting these conditions. -
HSD17B13 Inhibitor
HSD17B13-IN-83 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), exhibiting an IC50 value of ≤ 0.1 μM for estradiol. This compound is relevant for investigations into liver and metabolic disorders, including non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and drug-induced liver injury (DILI). Its specificity and efficacy make it a valuable tool for advancing research in the fields of hepatology and cardiovascular health. -
HSD17B13 Inhibitor
HSD17B13-IN-56 is a selective inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), exhibiting an IC50 value of ≤ 0.1 μM for estradiol. This compound is crucial for investigating the role of HSD17B13 in various hepatic and metabolic disorders, including non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and drug-induced liver injury (DILI). Its potent inhibition makes it a valuable tool for advancing research in liver pathology and associated cardiovascular conditions. -
HSD17B13 Inhibitor
HSD17B13-IN-51 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of ≤ 0.1 μM for estradiol. This compound is valuable for research into liver diseases, including non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), as well as drug-induced liver injury (DILI). Its specific targeting of HSD17B13 positions it as a critical tool for investigating metabolic and cardiovascular disease pathways. -
17BHSD13 Inhibitor
HSD17B13-IN-105 is a selective inhibitor of 17β-hydroxysteroid dehydrogenase 13 (17BHSD13), exhibiting an IC50 value of 0.036 μM and notable selectivity against 17BHSD4 with an IC50 of 31.5 μM. This compound is valuable for research applications targeting liver diseases, particularly non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). Its specificity and potent inhibition profile make it a significant tool for studying the biochemical pathways involved in these conditions. -
HSD17B13 Inhibitor
HSD17B13-IN-48 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), exhibiting an IC50 value of ≤ 0.1 μM for estradiol. This compound is valuable for investigating liver diseases, metabolic disorders, and cardiovascular conditions, including non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and drug-induced liver injury (DILI). Its inhibitory action on HSD17B13 makes it a crucial tool for research into the pathophysiology and therapeutic targeting of these conditions. -
HSD17B13 Inhibitor
HSD17B13-IN-82 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), exhibiting an IC50 value of ≤ 0.1 μM for estradiol. This compound is valuable for investigating the role of HSD17B13 in liver diseases, including non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), as well as in metabolic and cardiovascular disorders. Additionally, HSD17B13-IN-82 is useful for studying drug-induced liver injury (DILI) and its underlying mechanisms. -
AKR1C3 Inhibitor
Indomethacin methylester is a selective inhibitor of AKR1C3, exhibiting an IC50 of 5.67 μM. This compound is particularly relevant for studying its role in prostate cancer research, where it may aid in elucidating the mechanisms underlying tumor progression and therapeutic resistance. Its specificity for AKR1C3 offers potential insights into targeting this enzyme for cancer treatment strategies. -
HSD17B13 Inhibitor
HSD17B13-IN-71 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), exhibiting an IC50 value of ≤ 0.1 μM for estradiol. This compound is valuable for research targeting liver diseases, metabolic disorders, and cardiovascular conditions, including non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). Additionally, HSD17B13-IN-71 can aid in investigations of drug-induced liver injury (DILI), making it a crucial tool in related biological studies. -
HSD17B13 Inhibitor
HSD17B13-IN-104 is a potent and selective inhibitor of HSD17B13, exhibiting an IC50 of 2.5 nM. This compound effectively modulates hepatic lipid metabolism by targeting the SREBP-1c/FAS signaling pathway, thereby reducing hepatic lipid accumulation. HSD17B13-IN-104 holds potential for advancing research on metabolic dysfunction-associated steatohepatitis and related conditions. -
HSD17B13 Inhibitor
HSD17B13-IN-95 is a potent inhibitor of 17 β-hydroxysteroid dehydrogenase (HSD17B13), with an IC50 value for estradiol of less than 0.1 μM. This compound is useful in the investigation of nonalcoholic fatty liver disease and other metabolic disorders associated with altered steroid hormone metabolism. Its ability to effectively modulate HSD17B13 activity makes it a valuable tool for research into the biological mechanisms underlying liver function and related pathologies. -
HSD17B13 Inhibitor
HSD17B13-IN-72 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), exhibiting an IC50 value of less than 0.1 μM for estradiol. This compound is valuable for studying the role of HSD17B13 in liver diseases and metabolic disorders, facilitating research into potential therapeutic interventions and mechanisms underlying these conditions. Its high specificity makes it an important tool for elucidating the biological pathways associated with steroid metabolism. -
HSD17B13 Inhibitor
HSD17B13-IN-55 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of ≤ 0.1 μM for estradiol. This compound is valuable for investigating liver diseases, including non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), as well as metabolic and cardiovascular disorders. Additionally, it may support research into drug-induced liver injury (DILI), providing insights into its mechanisms and potential therapeutic interventions. -
HSD17B13 Inhibitor
HSD17B13-IN-61 is a specific inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), demonstrating an IC50 value of ≤ 0.1 μM for estradiol. This compound is intended for research into liver-related conditions, including non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and drug-induced liver injury (DILI), as well as various metabolic and cardiovascular diseases. Its high potency makes it a valuable tool for investigating the role of HSD17B13 in these disease contexts. -
17β-HSD Inhibitor
HSD17B13-IN-21 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), exhibiting an IC50 of less than 0.1 μM for estradiol and less than 1 μM for leukotriene B3. This compound is significant in the study of nonalcoholic fatty liver diseases (NAFLDs), including nonalcoholic steatohepatitis (NASH). Its application in research could provide insight into the mechanisms underlying liver-related metabolic disorders. -
HSD17B13 Inhibitor
HSD17B13-IN-12 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), demonstrating an IC50 value of ≤ 0.1 μM for both leukotriene B3 and estradiol. This compound is valuable for studying liver diseases, metabolic disorders, and cardiovascular conditions, including non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and drug-induced liver injury (DILI). Its targeted inhibition offers insights into the biochemical pathways associated with these health issues. -
HSD17B13 Inhibitor
HSD17B13-IN-54 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of ≤ 0.1 μM for estradiol. This compound is valuable for investigating the role of HSD17B13 in various pathologies, including liver diseases, metabolic disorders, and cardiovascular conditions such as non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). Additionally, it serves as a useful tool for studying drug-induced liver injury (DILI). -
HSD17B13 Inhibitor
HSD17B13-IN-96 is a potent inhibitor of 17 β-hydroxysteroid dehydrogenase (HSD17B13), exhibiting an IC50 value for estradiol of less than 0.1 μM. This compound is primarily utilized in research focused on nonalcoholic fatty liver disease (NAFLD) and related metabolic disorders. Its effectiveness in modulating HSD17B13 activity provides valuable insights into the biological pathways involved in liver metabolism and pathology. -
HSD17B13 Inhibitor
HSD17B13-IN-79 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), demonstrating an IC50 value of ≤ 0.1 μM for estradiol. This compound is valuable for investigating liver diseases, metabolic disorders, and cardiovascular conditions, including non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and drug-induced liver injury (DILI). HSD17B13-IN-79 serves as an important tool for research aimed at understanding the role of HSD17B13 in these pathological conditions. -
HSD17B13 Inhibitor
HSD17B13-IN-91 is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value for estradiol ranging between 0.1 μM and 0.5 μM. This compound is utilized in research contexts focusing on liver diseases, including non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), as well as metabolic disorders and cardiovascular diseases. Additionally, it is relevant for studying drug-induced liver injury (DILI), making it a valuable tool for understanding the role of HSD17B13 in various pathological conditions. -
HSD17B13 Inhibitor
HSD17B13-IN-77 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of less than 0.1 μM for estradiol. This compound is valuable for research related to liver diseases and metabolic disorders, providing insight into the role of HSD17B13 in various physiological and pathological processes. Its application may enhance understanding of steroid metabolism and its implications in health and disease. -
HSD17B13 Inhibitor
HSD17B13-IN-20 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13). This compound plays a crucial role in the modulation of estrogen metabolism and is particularly relevant in the study of liver diseases, including hepatitis, liver fibrosis, liver cirrhosis, and hepatocellular carcinoma. HSD17B13-IN-20 provides valuable insights into the therapeutic targeting of HSD17B13 for the treatment and understanding of hepatic disorders. -
HSD17B13 Inhibitor
HSD17B13-IN-68 is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), demonstrating an IC50 value of less than 0.1 μM for estradiol. This compound is valuable for investigating the role of HSD17B13 in liver diseases and metabolic disorders, providing insights into potential therapeutic targets and mechanisms of action in these conditions. Its potency and specificity make it a useful tool for research in endocrinology and metabolic pathways. -
HSD17B13 Inhibitor
HSD17B13-IN-64 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of ≤ 0.1 μM for estradiol. This compound is valuable for research focused on liver diseases, including non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), as well as metabolic disorders and drug-induced liver injury (DILI). Its selective inhibition of HSD17B13 may provide insights into therapeutic strategies for these conditions. -
17β-HSD10 Inhibitor
ESC1002755 is a selective inhibitor of 17β-HSD10, exhibiting an IC50 of 19 nM and demonstrating non-competitive inhibition against the cofactor NADH. This compound shows minimal cytotoxicity in HEK293 cells at a concentration of 50 μM, making it a promising tool for studies related to Alzheimer’s disease and hormone-dependent cancers, including prostate, bone, and colorectal cancer. Research applications include exploring the enzymatic mechanisms and therapeutic interventions associated with these conditions. -
HSD17B13 Inhibitor
HSD17B13-IN-11 is a selective inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), exhibiting potent activity with an IC50 of ≤ 1 μM for leukotriene B3 and ≤ 0.1 μM for estradiol. This compound is valuable for investigating liver pathologies, including non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and drug-induced liver injury (DILI). Its role in metabolic and cardiovascular research also supports its utility in exploring potential therapeutic interventions. -
HSD17B13 Inhibitor
HSD17B13-IN-38 is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13). This compound plays a significant role in the regulation of steroid metabolism and has potential implications in the study of liver and metabolic diseases, including non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). Researchers can utilize HSD17B13-IN-38 to explore its impact on cardiovascular diseases and related metabolic pathways. -
17β-HSD Inhibitor
HSD17B13-IN-23 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), exhibiting an IC50 of less than 0.1 μM for estradiol and below 1 μM for leukotriene B3. This compound is significant in the study of nonalcoholic fatty liver diseases (NAFLDs), particularly in relation to nonalcoholic steatohepatitis (NASH). Its capacity to modulate HSD17B13 activity makes it a valuable tool for investigating the biochemical pathways involved in hepatic lipid metabolism and related disorders. -
HSD17B13 Inhibitor
HSD17B13-IN-88 is a potent inhibitor of 17β-Hydroxysteroid dehydrogenase 13 (HSD17B13), exhibiting an IC50 value of ≤0.1 μM for estradiol. This compound selectively modulates steroid hormone metabolism and has significant implications for research in metabolic disorders and liver diseases. Its ability to influence estradiol levels makes it a valuable tool for studying hormone-related pathways and therapeutic strategies. -
HSD17B13 Inhibitor
HSD17B13-IN-99 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of less than 0.1 μM for estradiol. This compound demonstrates significant potential for investigating liver diseases, metabolic disorders, and cardiovascular conditions, including non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and drug-induced liver injury (DILI). Researchers can utilize HSD17B13-IN-99 to explore therapeutic strategies and mechanisms related to these health issues. -
HSD17B13 Inhibitor
HSD17B13-IN-22 is a selective inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13). This compound demonstrates significant biological activity in modulating lipid metabolism and is relevant in the study of liver-related disorders, including hepatitis, liver fibrosis, liver cirrhosis, and hepatocellular carcinoma. Its application in research enables a deeper understanding of HSD17B13's role in these conditions, potentially paving the way for therapeutic advancements. -
HSD17B13 Inhibitor
HSD17B13-IN-60 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of ≤ 0.1 μM for estradiol. This compound is primarily utilized in research related to liver and metabolic diseases, including non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and drug-induced liver injury (DILI). Its inhibition of HSD17B13 makes it a valuable tool for understanding the underlying mechanisms of these disorders and developing potential therapeutic strategies. -
17β-HSD Inhibitor
HSD17B13-IN-18 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), exhibiting an IC50 of less than 0.1 μM for estradiol and less than 1 μM for Leukotriene B3. This compound is significant in the context of nonalcoholic fatty liver diseases (NAFLDs), particularly in the study of nonalcoholic steatohepatitis (NASH). HSD17B13-IN-18 facilitates research aimed at understanding and potentially therapeutically targeting metabolic disorders related to liver function.
